Nanosilver: Safety, health and environmental effects and role in antimicrobial resistance by Hartemann, Philippe et al.




and role in antimicrobial
resistance
Philippe Hartemann, Peter Hoet, Ana Proykova*,
Teresa Fernandes, Anders Baun, Wim De Jong,
Juliane Filser, Arne Hensten, Carsten Kneuer,
Jean-Yves Maillard, Hannu Norppa, Martin
Scheringer, Susan Wijnhoven
European Commission, Scientific Committee on Emerging and Newly
Identified Health Risks (SCENIHR)
*Corresponding author :. Proykova, A. (SANTE-C2-SCIENTIFIC-
COMMITTEES@ec.europa.eu)
Considering emerging and newly
identified health risks
On request of the European Commission, the independent Scien-
tific Committee on Emerging and Newly Identified Health Risks
(SCENIHR) was requested to assess whether the use of nanosilver,
in particular in medical care or in consumer products, could result
in additional risks compared to more traditional uses of silver and
whether the use of nanosilver to control bacterial growth could
result in resistance of micro-organisms. The full text of the SCE-
NIHR Opinion is freely accessible [1]. This Comment looks at
several unresolved problems that require the attention of the
materials science community.
Silver (Ag) materials, including those at the nanoscale (nano-
silver), are widely used today for their antibacterial activity. How-
ever, the usefulness of (nano)silver in various medical applications
may be limited because of the increased resistance of micro-
organisms against silver.
The various silver compounds have different physico-chemical
properties, such as solubility and surface charge, which affect their122fate and biological activity. There are a lot of methods for produc-
tion and applications of nanosilver in food packaging materials,
food supplements (currently these two applications are not
allowed in the EU unless specifically authorized), dental materials,
textiles, electronics, household appliances, cosmetics, medical
devices, water disinfectants and room sprays.
Quantitative data on the life cycle of products containing
nanomaterials is in general extremely scarce. All silver content
in non-recycled waste will ultimately end up in the environment,
either as solid waste in landfills; emission from wastewater treat-
ment plants (in effluent water or in sludge); or as residual waste
from incineration plants (e.g., fly ash, slag or bottom ash). No
actual measurements of the incineration of nanosilver-containing
products exist, but depending on the type of nanomaterial, models
predict a release of 25–100% of air-borne NPs, which are effectively
caught by the filter systems. In Europe, the main environmental
exposure route of silver compounds in textiles and cosmetics will
be through wastewater treatment plants. Measurements of nano-
materials in consumer products and their release into the envi-
ronment are therefore urgently needed.
Nanosilver undergoes several transformations when it is released
into the environment. After aggregation and agglomeration, the
important ones are dissolution and subsequent speciation, such as
formation of silver chloride and silver sulphide. Silver sulphide is
particularly important because it is highly stable; sulphide is avail-
able in wastewater treatment plants and also in many freshwater
bodies. The chemical species that are present determine the bio-
availability and toxicity of silver in the environment. A large frac-
tion of the silver released to freshwater bodies sorbs to suspended
particulate matter and is transferred to the sediments, where it may
be stored, accumulate, or undergo transformations or resuspension
depending on physical, chemical, and biological conditions.
Two important points need to be taken into consideration.
Firstly, not all conventional methods used to assess Ag-NP solu-
bility are able to reflect Ag+ availability and, secondly, assessing the
dynamic interactions between Ag-NPs and biotic receptors, in-
cluding the sustained delivery of Ag+ is likely to be complex and
has not yet been studied.
The main target organs for silver nano-particles (Ag-NPs) distri-
bution after systemic availability are the spleen, liver and kidney.1369-7021/ 2015 Published by Elsevier Ltd. http://dx.doi.org/10.1016/j.mattod.2015.02.014







TRecent data indicate that some persistence of Ag may occur in the
brain and testes. For distribution of silver to the brain it is not clear
whether the silver is present in the brain tissue or limited to the
endothelium of the brain.
There is some evidence that ionic Ag may form silver structures
at the nanoscale in vivo. Presence of Ag in feces after intravenous
and subcutaneous administrations indicates biliary excretion of
Ag originating from parentally administered Ag-NPs.
A limitation of toxicokinetic studies on nanosilver is that most
of them used inductively coupled plasma mass spectrometer (ICP-
MS) or Atomic absorption spectrometry (AAS) for detection of the
Ag, so it cannot be definitively concluded that Ag-NPs are distrib-
uted to the organs, since all nanoparticles need to be completely
dissolved to run the analytical assays. Nevertheless, more detailed
studies suggest uptake in cells/organs through a combination of
cellular uptake routes like ion transportation and endocytosis of
particles. This would give rise to a delivery route for Ag-NPs that is
different from what is known for dissolved species of silver and will
thereby constitute a ‘nano-specific’ exposure.
In vitro studies show that cytokine production in macrophages
can be induced by nanosilver. In vivo studies could not clearly
show whether oral exposure to silver nanoparticles consistently
results in alterations of the non-specific immune responses. In
vitro, several of the studies reported genotoxic effects of nanosil-
ver. The controversial results may be explained by differences in
Ag-NP coating/shapes, cell type used, the cellular uptake, intra-
cellular dissolution, genotoxicity endpoint, and the way the cells
were exposed. As the studies available on the in vivo genotoxicityof Ag-NPs are few and concern Ag-NPs of variable characteristics,
further studies are required to conclude whether Ag-NPs could be
genotoxic in vivo. The possibility of secondary genotoxic effects
associated with inflammation and oxidative stress induced by
silver nanoparticles has not been studied.
The mode of action of silver is mainly attributed to the release of
silver ions. Ionic silver has a broad spectrum of antimicrobial
activity against planktonic and sessile bacteria and it is generally
considered to interact with multiple microbial target sites – micro-
bial proteins – with eventually structural and metabolic disruption.
Ag-NP properties may also account for some bacterial toxicity effect.
There is evidence of an effect of Ag-NPs on the composition of
bacterial flora and on the bacterial adaptation associated with
certain conditions and uses. Similar to ionic silver, bacterial resis-
tance has been demonstrated for Ag-NPs as well. However, evi-
dence is often fragmentary and focused on a few specific cases.
There is a paucity of information on the resistance mechanisms to
Ag-NPs. Exposure to ionic silver and Ag-NPs produces a stress-
response and affects gene expression.
More data is needed to better understand bacterial response to
ionic silver and Ag-NPs exposure. Regarding the hazard associated
with the dissemination of a resistance mechanism following the
use of Ag-NPs, no documentation is currently available, represent-
ing a serious gap of knowledge.
Further reading
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